The studies in Dr. Anne Le's laboratory primarily focus on cancer metabolism and metabolic aspects of other diseases. Using metabolomics technologies, their studies have led to breakthrough discoveries revealing several characteristic features of the metabolism of cancer (PMID: 22225880). One of these, the dependence of cancer cells on glutamine metabolism, has translated into clinical trials as a novel therapy for cancer patients. They further tracked the metabolic pathways in the remaining tumor after this novel therapy and identified the best-suited drugs for combined synergistic therapy (PMID: 27559084). Recently, they uncovered a specific role of the neurotransmitter N-Acetyl-Aspartyl-Glutamate (NAAG) for the first time in cancer, suggesting the possible use of NAAG for tumor monitoring. Moreover, NAAG was identified as a glutamate reservoir in cancer (PMID: 30970252).
You can find out more about Dr. Anne Le's laboratory here.
The Le laboratory consists of a diverse group of researchers led by Dr. Anne Le who is responsible for leading and directing projects. Every member of the lab is passionate about creating innovative solutions for improving the lives of cancer patients. The research conducted in Le lab exploits the altered cellular metabolism found in many cancers for prognostic and therapeutic potential.
The Le laboratory is also in charge of Metabolomics Program which is part of Institute for Clinical and Translational Research (ICTR) -supported labs.
- Provides consultation to basic, clinical, and translational research teams regarding the feasibility, design, and costs of projects using metabolomics technologies (including mass spec and NMR-based metabolomics);
- Provides metabolomics approaches based on specific research projects/questions: ranging from simple assays to high-throughput approaches such as global metabolic profiling and stable isotope-13C, 15N-labeled on a wide variety of sample types;
- Provides extensive data analysis and suggests options for subsequent steps towards clinical implementation.
Examples of Metabolomics-Based Discovery of Metabolic Aspects of Cancer and Other Diseases:
Identify new metabolic pathways: PMID: 22225880, PMID: 30970252, PMID: 31231915
Identify metabolic target pathways upon a given metabolic inhibitor treatment in vivo: PMID: 27559084.
Monitor disease progression: PMID: 30970252
Overview: PMID: 31451214
Lab Website: Le Cancer Metabolism Research Laboratory
Technology Expertise Keywords
Cancer metabolism and metabolic aspects of other diseases- Metabolomics technologies
Upregulation of the Glutaminase II Pathway Contributes to Glutamate Production upon Glutaminase 1 Inhibition in Pancreatic Cancer. Proteomics. 2019 Jun 24:e1800451.PMID: 31231915. Selected Publication in which Dr. Le is Corresponding author.
Uncovering the Role of N-Acetyl-Aspartyl-Glutamate as a Glutamate Reservoir in Cancer. Cell Rep. 2019 Apr 9;27(2):491-501. PMID: 30970252 Selected Publication in which Dr. Le is Corresponding author.
Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer. Proc Natl Acad Sci U S A. 2016 Aug 24. PMID: 27559084 Selected Publication in which Dr. Le is Corresponding author.
Tumorigenicity of hypoxic respiring cancer cells revealed by a hypoxia–cell cycle dual reporter. Proc Natl Acad Sci U S A. 2014 Aug 26; 111(34): 12486–12491. PMID: 25114222, Selected Publication in which Dr. Le is Corresponding author.
Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 2012 Jan 4;15(1):110-21. PMID: 22225880. Selected Publication in which Dr. Le is Corresponding author.